Business Daily Media

Men's Weekly

.

Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site

  • Written by PR Newswire
  • The new proof of mechanism trial in ulcerative colitis had its first patient dosed in New Zealand
  • In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via rectal administration

SEONGNAM, South Korea, June 2, 2021 /PR...

Small business backlash builds as RBA’s surcharge ban risks fuelling inflation

Australia’s small business sector has launched a fierce campaign against the Reserve Bank of Australia’s (RBA) proposed ban on debit and credit card...

Australia’s Young Entrepreneurs Redefining Success Through Legacy and Community Impact

A new generation of young Australian small business owners is redefining success, driven by a desire to create a lasting legacy through the positi...

Lessons in AI: How LoanOptions.ai Shows What Smart Adoption Really Looks Like

In a world where many small businesses are still trying to work out how to actually use AI (not just talk about it), Australian fintech LoanOption...

Driving smarter: how car subscription models are redefining mobility and financial flexibility

The world of mobility is changing fast, and car ownership is no longer the default. Across Australia, professionals and businesses alike are seeki...

The Future of Wealth Technology

“You shouldn’t need a large account balance to experience real-time investing. Technology should make that kind of access universal.” For decades...

Thryv wins national accolade at 2025 Australian Service Excellence Awards

  Thryv® (NASDAQ: THRY), Australia’s provider of the leading small business marketing and sales software platform, announced that Greg Nicolle, G...